Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abeona Therapeutics Inc ABEO

Healthcare Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The... see more

Recent & Breaking News (NDAQ:ABEO)

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 1, 2024

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

GlobeNewswire March 18, 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 5, 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 1, 2024

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

GlobeNewswire February 1, 2024

Abeona Therapeutics Announces $50 Million Credit Facility

GlobeNewswire January 8, 2024

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 15, 2023

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

GlobeNewswire November 27, 2023

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

GlobeNewswire November 13, 2023

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2023

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

GlobeNewswire September 26, 2023

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

GlobeNewswire September 12, 2023

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire September 7, 2023

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

GlobeNewswire August 30, 2023

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

GlobeNewswire August 8, 2023

Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023

GlobeNewswire July 28, 2023

Abeona Therapeutics Joins Rare Disease Company Coalition

GlobeNewswire July 19, 2023

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire July 7, 2023

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire July 3, 2023

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

GlobeNewswire June 9, 2023